fingolimod hydrochloride has been researched along with Bile Duct Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, H; Aoki, M; Hylemon, P; Sarkar, J; Takabe, K; Wu, R; Zhou, H | 1 |
| Jiang, H; Liang, Y; Liu, L; Lu, Z; Pan, S; Pei, T; Song, R; Wang, J; Yin, D; Zheng, T | 1 |
2 other study(ies) available for fingolimod hydrochloride and Bile Duct Cancer
| Article | Year |
|---|---|
Conjugated Bile Acids Accelerate Progression of Pancreatic Cancer Metastasis via S1PR2 Signaling in Cholestasis.
Topics: Animals; Bile Acids and Salts; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholestasis; Fingolimod Hydrochloride; Humans; Liver Neoplasms; Mice; Pancreatic Neoplasms; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Steroids | 2023 |
FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Topics: Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Metastasis; Phosphorylation; Propylene Glycols; Signal Transduction; Sphingosine; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |